664 860
[4]
Petrelli F, Coinu A, Cabiddu M, Ghilardi M, Vavassori I, Barni S. Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystec- tomy: a meta-analysis. Eur Urol 2014;65:350–7.
[5]
Zargar H, Espiritu PN, Fairey AS, et al. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol 2015;67:241–9.[6]
Faltas BM, Prandi D, Tagawa ST, et al. Clonal evolution of chemo- therapy-resistant urothelial carcinoma. Nat Genet 2016;48:1490–9.[7]
Sonpavde G, Goldman BH, Speights VO, et al. Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemother- apy. Cancer 2009;115:4104–9.[8]
Chappidi MR, Kates M, Brant A, et al. Assessing cancer progression and stable disease after neoadjuvant chemotherapy for organ- confined muscle-invasive bladder cancer. Urology 2017;102: 148–58.[9]
Rosenblatt R, Sherif A, Rintala E, et al. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle- invasive urothelial bladder cancer. Eur Urol 2012;61:1229–38.[10]
Seisen T, Sonpavde G, Kachroo N, et al. Comparative effectiveness of selective adjuvant versus systematic neoadjuvant chemotherapy- based strategy for muscle-invasive urothelial carcinoma of the bladder. Eur Urol Suppl 2017;16:e291.
[11]
Plimack ER, Dunbrack RL, Brennan TA, et al. Defects in DNA repair genes predict response to neoadjuvant cisplatin-based che- motherapy in muscle-invasive bladder cancer. Eur Urol 2015;68: 959–67.
[12]
Liu D, Plimack ER, Hoffman-Censits J, et al. Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma. JAMA Oncol 2016;2:1094–6.
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 6 6 0 – 6 6 4
664